Sign In
Buy ACON
$3.49
-0.0100 (-0.286%)
At Close: Jun 03, 2026
Aclarion Provides 2025 Update and 2026 Corporate Outlook
06:00am, Thursday, 08'th Jan 2026
BROOMFIELD, Colo., January 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Provides 2025 Update and 2026 Corporate Outlook
06:00am, Thursday, 08'th Jan 2026
Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of Dece
BROOMFIELD, Colo., Jan. 06, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and opera
Ramsay Health Care (OTCMKTS:RMYHY) vs. Aclarion (NASDAQ:ACON) Financial Review
02:00am, Thursday, 11'th Dec 2025
Aclarion (NASDAQ: ACON - Get Free Report) and Ramsay Health Care (OTCMKTS:RMYHY - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses ba
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
08:01am, Thursday, 04'th Dec 2025
BROOMFIELD, Colo., December 4, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
08:00am, Thursday, 04'th Dec 2025
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine car
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
08:00am, Tuesday, 02'nd Dec 2025
Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough technol
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
06:10am, Wednesday, 05'th Nov 2025
Broomfield, CO, November 5, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
06:00am, Wednesday, 05'th Nov 2025
Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in
Short Interest in Aclarion, Inc. (NASDAQ:ACON) Increases By 535.7%
01:58am, Thursday, 30'th Oct 2025
Aclarion, Inc. (NASDAQ: ACON - Get Free Report) was the target of a large growth in short interest in October. As of October 15th, there was short interest totaling 80,100 shares, a growth of 535.7% f
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
06:00am, Wednesday, 22'nd Oct 2025
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion's breakthrough Nociscan solution for chronic low back pain
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
06:13am, Tuesday, 14'th Oct 2025
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted), providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% yea
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
06:09am, Tuesday, 14'th Oct 2025
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year
Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D.
